Zobrazeno 1 - 10
of 36
pro vyhledávání: ''
Autor:
Ole A. Andreassen, Ingrid Dieset, Stian Lydersen, K.K. Fjukstad, Olav Spigset, Anne Engum, N. Eiel Steen
Publikováno v:
European Psychiatry. 48:71-78
BackgroundThe aim of this observational study was to investigate the relationship between metabolic factors and use of selective serotonin reuptake inhibitors (SSRIs) combined with olanzapine, quetiapine or risperidone.MethodsData from the Norwegian
Autor:
Rajiv T Erasmus, Laila Asmal, E. Van Niekerk, Piet Oosthuizen, Martin Kidd, Robin Emsley, Anil K. Malhotra, Bonginkosi Chiliza
Publikováno v:
European Psychiatry. 30:277-283
Objectives:To assess changes in body mass and metabolic profiles in patients with first-episode schizophrenia receiving standardised, assured treatment and to identify predictors and moderators of the effects.Methods:We investigated the changes in bo
Publikováno v:
European Psychiatry. 41:S370-S371
Antipsychotic drugs are currently used in clinical practice for a variety of mental disorders. Clozapine is the most effective medication for treatment-resistant schizophrenia, in controlling aggression and suicidal behavior in psychosis. Although cl
Autor:
Henrik Nybäck, Jan-Erik Strand
Publikováno v:
European Psychiatry. 20:50-54
Nicotine has been proposed to provide anxiety relief, oral gratification and self-medication of psychotic symptoms in psychiatric patients. In order to investigate the relations between psychopathology and tobacco use we measured the concentration of
Autor:
Ágota Barabássy, Judit Harsányi, István Bitter, Silvana Galderisi, M. Debelle, István Laszlovszky, György Németh, Balázs Szatmári, Suresh Durgam, E. Szalai
Publikováno v:
European Psychiatry. 33:s256-s257
ObjectiveTo examine the effect of cariprazine, a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, on predominant negative symptoms of schizophrenia.MethodsSubjects with schizophrenia and PANSS factor score for negati
Autor:
B. Fernández-Abascal Puente, L. Sánchez Blanco, R. Landera Rodríguez, M. Gómez Revuelta, O. Porta Olivares, D. Abejas Díez, J.L. Garcia Egea, M. Juncal Ruiz, M. Pérez Herrera, G. Pardo de Santayana Jenaro
Publikováno v:
European Psychiatry. 41:S268-S268
IntroductionAtypical anti-psychotics are associated with an impaired in glucose and lipids homeostasis.AimsTo evaluate, the effect in lipids and glucose levels after switching to long-acting injectable (LAI) aripiprazole.MethodsThis was a prospective
Autor:
A. Fontaine, G. Radu
Publikováno v:
European Psychiatry. 41:S650-S650
IntroductionWith 10 million of patients across the world, Parkinson's disease is the second most common form of neurodegeneration, after Alzheimer's. Among half of patients develop psychotic symptoms, such as visual hallucinations and delusions, whic
Publikováno v:
European Psychiatry. 41:s829-s829
IntroductionApproximately a third of patients with schizophrenia show limited response to antipsychotic medication. As several studies have been suggesting new classifications to schizophrenia, our aim is to review different hypothesis and seek a new
Autor:
Ágota Barabássy, Judit Harsányi, E. Szalai, Balázs Szatmári, István Laszlovszky, György Németh
Publikováno v:
European Psychiatry. 41:S270-S270
IntroductionNegative symptoms have substantial impact on day-to-day functioning of patients with schizophrenia affecting their ability to perform activities of daily living and to maintain personal relationships.ObjectiveTo present post hoc data on d
Autor:
P. Torres, A. Fernandez, M. Tur, C. Caballero, E. Contreras, C. Merino, E. Esmeralda, C. Torres, S.V. Boned, M. De Almuedo, S. Latorre, M. Guisado, G. Herrero, S. Ramos-Perdigues, M. Segura, M.T. Sanchez, E. Sanchez, M.J. Gordillo
Publikováno v:
European Psychiatry. 41:s502-s502
IntroductionClozapine (CZP) is the only antipsychotic approved for resistant schizophrenia 1. Due to its side effects, CZP is not the first therapeutic option in a psychotic episode. Its anticholinergic effects often cause constipation, however, diar